Aligos Therapeutics, Inc. Pre-Tax Income
Aligos Therapeutics, Inc. (ALGS) reported Pre-Tax Income of $1.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-06
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $1.31M.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$22.72M, a 152.68% decline year-over-year.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$19.85M.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$31.48M.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$23.88M.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$130.88M.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$86.88M.
- Aligos Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$95.94M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.31M 10-Q · filed 2026-08-06 | -$21.42M 10-Q · filed 2026-08-06 | -$41.27M derived: sum of 3 quarters · filed 2026-08-06 | -$72.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$22.72M 10-Q · filed 2026-05-07 | -$42.57M derived: sum of 2 quarters · filed 2026-05-07 | -$74.06M derived: sum of 3 quarters · filed 2026-05-07 | -$89.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$19.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$51.33M derived: sum of 2 quarters · filed 2026-03-05 | -$67.01M derived: sum of 3 quarters · filed 2026-08-06 | -$23.88M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$31.48M 10-Q · filed 2025-11-06 | -$47.16M derived: sum of 2 quarters · filed 2026-08-06 | -$4.03M 10-Q · filed 2025-11-06 | -$86.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.68M 10-Q · filed 2026-08-06 | $27.45M 10-Q · filed 2026-08-06 | -$54.67M derived: sum of 3 quarters · filed 2026-08-06 | -$73.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $43.13M 10-Q · filed 2026-05-07 | -$38.99M derived: sum of 2 quarters · filed 2026-05-07 | -$58.16M derived: sum of 3 quarters · filed 2026-05-07 | -$52.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$82.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$101.29M derived: sum of 2 quarters · filed 2026-03-05 | -$96.04M derived: sum of 3 quarters · filed 2026-03-05 | -$130.88M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$19.17M 10-Q · filed 2025-11-06 | -$13.92M derived: sum of 2 quarters · filed 2025-11-06 | -$48.76M 10-Q · filed 2025-11-06 | -$76.68M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.25M 10-Q · filed 2025-08-06 | -$29.59M 10-Q · filed 2025-08-06 | -$57.51M derived: sum of 3 quarters · filed 2025-08-06 | -$75.52M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$34.84M 10-Q · filed 2025-05-06 | -$62.76M derived: sum of 2 quarters · filed 2025-05-06 | -$80.77M derived: sum of 3 quarters · filed 2025-05-06 | -$98.81M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$27.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$45.93M derived: sum of 2 quarters · filed 2025-03-10 | -$63.97M derived: sum of 3 quarters · filed 2025-03-10 | -$86.88M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$18.01M 10-Q · filed 2024-11-06 | -$36.05M derived: sum of 2 quarters · filed 2024-11-06 | -$58.96M 10-Q · filed 2024-11-06 | -$80.80M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$18.03M 10-Q · filed 2024-08-06 | -$40.95M 10-Q · filed 2024-08-06 | -$62.79M derived: sum of 3 quarters · filed 2024-08-06 | -$81.45M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$22.92M 10-Q · filed 2024-05-07 | -$44.75M derived: sum of 2 quarters · filed 2024-05-07 | -$63.42M derived: sum of 3 quarters · filed 2024-05-07 | -$83.29M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$21.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$40.50M derived: sum of 2 quarters · filed 2024-03-12 | -$60.38M derived: sum of 3 quarters · filed 2024-03-12 | -$95.94M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$18.66M 10-Q · filed 2023-11-02 | -$38.54M derived: sum of 2 quarters · filed 2023-11-02 | -$74.10M 10-Q · filed 2023-11-02 | -$111.88M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$19.88M 10-Q · filed 2023-08-03 | -$55.44M 10-Q · filed 2023-08-03 | -$93.21M derived: sum of 3 quarters · filed 2023-08-03 | -$126.21M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$35.56M 10-Q · filed 2023-05-04 | -$73.33M derived: sum of 2 quarters · filed 2023-05-04 | -$106.33M derived: sum of 3 quarters · filed 2023-05-04 | -$136.12M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$37.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$70.77M derived: sum of 2 quarters · filed 2023-03-09 | -$100.56M derived: sum of 3 quarters · filed 2023-03-09 | -$128.19M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$33.00M 10-Q · filed 2022-11-02 | -$62.79M derived: sum of 2 quarters · filed 2022-11-02 | -$90.42M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | -$29.79M 10-Q · filed 2022-08-04 | -$57.42M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$27.63M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | -$108.38M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |